Worth reading
50Recurring
Scored from 4 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
7.6
Year-on-year change (revenue, %)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2024年9月1日〜2024年11月30日ConsolidatedJapanese GAAPNet Sales7,655¥ millionYear on year +7.6%
Operating profit2,107¥ millionYear on year -5.2%
Ordinary income2,298¥ millionYear on year -2.2%
Net income attributable to owners of the parent1,598¥ millionYear on year +1.6%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets57,334¥ million
of which net assets 52,345 ¥ million
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Segment revenueSurgical-related products ¥2,442 million (YoY +25.5%), Ailess needle-related products ¥2,844 million (YoY +12.9%), Dental Products ¥2,368 million (YoY -10.6%)
Segment profitSurgical-related products ¥838 million (YoY +28.8%), Ailess needle-related products ¥1,046 million (YoY +8.2%), Dental Products ¥222 million (YoY -63.2%)
Regional salesRegion Japan / Surgical-related products ¥643 million / Ailess needle-related products ¥222 million / Dental Products ¥287 million, Region Asia / Surgical-related products ¥660 million / Ailess needle-related products ¥1,351 million / Dental Products ¥1,428 million, Region Europe / Surgical-related products ¥682 million / Ailess needle-related products ¥445 million / Dental Products ¥373 million, Region North America / Surgical-related products ¥151 million / Ailess needle-related products ¥433 million / Dental Products ¥175 million, Region Other / Surgical-related products ¥305 million / Ailess needle-related products ¥391 million / Dental Products ¥103 million
Outlook and shareholder returns
Full-year earnings forecast
Net SalesNot disclosed
Operating profitNot disclosed
Ordinary incomeNot disclosed
Net incomeNot disclosed
Remarks2024年10月7日公表数値から変更なし
Revision to Earnings ForecastNo change
Factors Behind Changes in Business Performance
欧州地域でサージカル関連製品の販売が好調。中国を中心としたアジア地域でアイレス針関連製品の販売が増加。一方、中国経済の停滞に伴うデンタル市況の悪化、歯科用回転切削機器の回収影響及び歯科根管治療における手技の変化により、デンタル関連製品の販売が低調。決算賞与、人件費等の増加により販売費及び一般管理費が増加。法人税等調整額の減少により最終利益が増加。
Disclosure regarding the going concern assumption
No applicable matters
Material subsequent eventsNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥12 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥0 million, Other ¥3 million
Depreciation and amortization¥569 million
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年9月1日〜2024年11月30日 |
| Net Sales | ¥7,655 million (YoY +7.6%) |
| Operating profit | ¥2,107 million (YoY -5.2%) |
| Ordinary income | ¥2,298 million (YoY -2.2%) |
| Profit attributable to owners of the parent | ¥1,598 million (YoY +1.6%) |
| Total assets | ¥57,334 million |
| Net assets | ¥52,345 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Remarks 2024年10月7日公表数値から変更なし |
| Revision to Earnings Forecast | No change |
| Segment revenue | Surgical-related products ¥2,442 million (YoY +25.5%), Ailess needle-related products ¥2,844 million (YoY +12.9%), Dental Products ¥2,368 million (YoY -10.6%) |
| Segment profit | Surgical-related products ¥838 million (YoY +28.8%), Ailess needle-related products ¥1,046 million (YoY +8.2%), Dental Products ¥222 million (YoY -63.2%) |
| Regional sales | Region Japan / Surgical-related products ¥643 million / Ailess needle-related products ¥222 million / Dental Products ¥287 million, Region Asia / Surgical-related products ¥660 million / Ailess needle-related products ¥1,351 million / Dental Products ¥1,428 million, Region Europe / Surgical-related products ¥682 million / Ailess needle-related products ¥445 million / Dental Products ¥373 million, Region North America / Surgical-related products ¥151 million / Ailess needle-related products ¥433 million / Dental Products ¥175 million, Region Other / Surgical-related products ¥305 million / Ailess needle-related products ¥391 million / Dental Products ¥103 million |
| Depreciation and amortization | ¥569 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥12 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥0 million, Other ¥3 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Material subsequent events | No applicable matters. |
| Factors Behind Changes in Business Performance | 欧州地域でサージカル関連製品の販売が好調。中国を中心としたアジア地域でアイレス針関連製品の販売が増加。一方、中国経済の停滞に伴うデンタル市況の悪化、歯科用回転切削機器の回収影響及び歯科根管治療における手技の変化により、デンタル関連製品の販売が低調。決算賞与、人件費等の増加により販売費及び一般管理費が増加。法人税等調整額の減少により最終利益が増加。 |
Items this document does not state (18)
Net income per shareOperating MarginEquity ratioCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodAnnual Dividend ForecastPayout ratioShareholder Return PolicyOrders received and order backlogImpairment lossChange in accounting policyChanges in the scope of consolidationAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.主に欧州地域でサージカル関連製品の販売が好調に推移し、中国を中心としたアジア地域でアイレス針関連製品の販売が増加した一方、中国においてデンタル関連製品の販売が低調に推移した。売上原価は微減となった一方、前期業績に伴う決算賞与の計上及び人件費等の増加により販売費及び一般管理費が増加した。法人税等調整額の減少により、親会社株主に帰属する四半期純利益は増加した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.